Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...
pharmaphorum23h
End looms for Cassava's simufilam in Alzheimer's disease
Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...
STAT1d
Cassava Sciences and its Alzheimer’s drug are done. The damage lingers
The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...
What’s left in Cassava after Phase 3 setback for Alzheimer’s drug
Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...
thedeepdive15h
Cassava Sciences Stock Plummets Amid Trial Failure and Shkreli’s Takedown
Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...
Cassava to stop trials of Alzheimer's drug after late-stage study failure
(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a ...
Zacks.com on MSN14h
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...
STAT1d
Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news
Yesterday, the story ended exactly as I and many others knew it would — with the company’s experimental drug for Alzheimer’s ...
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...
Cassava plummets 86% as simufilam phase 3 Alzheimer's trial misses endpoints
Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer's disease candidate simufilam did ...